CASI Pharmaceuticals Inc (NASDAQ:CASI)

Data as of Jan 30
 -0.0699 / -4.21%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

CASI Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. Its drug candidate, ENMD 2076, which is an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. The company was founded in 1991 and is headquartered in Rockville, MD.

Contact Information

CASI Pharmaceuticals, Inc.
9620 Medical Center Drive
Rockville Maryland 20850
P:(240) 864-2600
Investor Relations:
(240) 864-2643



Other institutional8.38%
Mutual fund holders1.54%
Individual stakeholders0.31%

Top Executives

Ken Keyong RenChief Executive Officer & Director
Cynthia Wong HuCOO, Secretary, Vice President & General Counsel
Sara B. CapitelliChief Accounting Officer & Vice President-Finance
William E. GannonVice President-Medical & Regulatory Affairs
Ginny DunnAssociate Director-Investor Relations

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.